Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 415

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 415
---
 product candidates;                             |

| • |     | collaboration agreements may not lead to development or commercialization of FYARRO or any other product 
 candidates that we may develop in the future in the most efficient manner or at all;                     |

| • |     | collaborators may not provide us with timely and accurate information regarding development progress and                                                                                                                                                  
 activities under the collaboration or may limit our ability to share such information, which could adversely impact our ability to report progress to our investors and otherwise plan our own development of FYARRO or any other product candidates that 
 we may develop in the future;                                                                                                                                                                                                                             |

| • |     | collaborators may own or co-own intellectual property covering our                                                                                                          
 products that results from us collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and |

| • |     | a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable 
 laws, resulting in civil or criminal proceedings.                                                            |

Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements. For example, on June 27, 2022, EOC elected to terminate the EOC License Agreement, effective immediately, due to alleged material breaches by us. See Notes 7 and 12 to our Interim Condensed Financial Statements for the Nine Months Ended September 30, 2024 included herein for more information about the EOC License Agreement, its termination, and resulting arbitration (including the arbitration panel’s final award in our favor). Under the EOC License Agreement, we relied on EOC for a substantial portion of the financial resources and for the development, regulatory, and commercialization activities for FYARRO in the EOC Territory. In addition, EOC’s termination of the EOC License Agreement prior to completing development or commercialization of FYARRO under the collaboration adversely impacts the potential approval and our revenue from the licensed product in the EOC Territory and we will not receive future revenues from the collaboration. It may be necessary for us to assume the responsibility at our own expense for the development of FYARRO in the EOC Territory or find another partner for the territory. In that event, we would likely need to seek additional funding and our potential to generate future revenues from FYARRO could be significantly reduced and our business could